Used as a potent and selective inhibitor of NAMPT (nicotinamide phosphoribosyltransferase), NDI-091143 is primarily applied in cancer research to disrupt NAD+ biosynthesis in tumor cells. By targeting this key metabolic enzyme, it induces energy depletion and cell death in cancer models, particularly those with high NAD+ turnover. It serves as a valuable tool compound for studying NAD+ metabolism and evaluating the therapeutic potential of NAMPT inhibition in oncology. Its selectivity and pharmacokinetic profile make it suitable for in vitro and in vivo studies exploring metabolic vulnerabilities in tumors.